GreenLight Biosciences (NASDAQ:GRNA – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.
Analyst Ratings
This is a breakdown of current ratings for GreenLight Biosciences and Arcellx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GreenLight Biosciences | 0 | 1 | 1 | 0 | 2.50 |
| Arcellx | 0 | 0 | 10 | 0 | 3.00 |
GreenLight Biosciences currently has a consensus price target of $4.75, indicating a potential upside of 1,485.98%. Arcellx has a consensus price target of $53.42, indicating a potential upside of 50.09%. Given GreenLight Biosciences’ higher probable upside, equities analysts clearly believe GreenLight Biosciences is more favorable than Arcellx.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GreenLight Biosciences | $10.20 million | 4.45 | -$167.05 million | ($1.14) | -0.26 |
| Arcellx | N/A | N/A | -$188.68 million | ($3.96) | -8.99 |
GreenLight Biosciences has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than GreenLight Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
GreenLight Biosciences has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Arcellx has a beta of -0.69, meaning that its stock price is 169% less volatile than the S&P 500.
Profitability
This table compares GreenLight Biosciences and Arcellx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GreenLight Biosciences | -1,521.00% | -374.26% | -122.78% |
| Arcellx | N/A | -46.20% | -25.29% |
Institutional & Insider Ownership
24.4% of GreenLight Biosciences shares are owned by institutional investors. 30.3% of GreenLight Biosciences shares are owned by insiders. Comparatively, 5.9% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
GreenLight Biosciences beats Arcellx on 8 of the 13 factors compared between the two stocks.
About GreenLight Biosciences
FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.
About Arcellx
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
